579 results for "Integration Therapy"
IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?
Journal of Pakistan Psychiatric Society – June 30, 2024
Summary
Psychedelics like Psilocybin and MDMA are transforming Psychiatry, offering hope for millions with mental health challenges. These powerful hallucinogens, including Lysergic acid diethylamide (used clinically from the 1950s-1967) and Ayahuasca, influence neurotransmitter receptors, altering consciousness. Clinical psychology and drug studies reveal their potential to disrupt pathological brain activity, promoting neuroplasticity. Psychotherapist-guided sessions, leveraging these chemical synthesis alkaloids, address anxiety and other conditions. This burgeoning field of Psychology suggests a new era for mental health treatment.
Abstract
Psychedelics, substances known to alter perception, mood, and consciousness, have been used across various cultures for centuries, often in religio...
The Evolved Psychology of Psychedelic Set and Setting: Inferences Regarding the Roles of Shamanism and Entheogenic Ecopsychology
Frontiers in Pharmacology – February 23, 2021
Summary
Psychedelics, particularly psilocybin, profoundly shaped human consciousness and psychology. Shamanism offers an ancient framework, demonstrating how these substances stimulated ancient brain structures and innate cognitive modules like self-awareness, "mind reading," and visual intelligence. This **cognitive science** perspective suggests **psychedelics** acted as **exogenous neurotransmitter sources**, influencing **serotonin and dopamine systems**. Integrating **shamanism** into modern **psychedelics and drug studies** can optimize therapeutic settings, leveraging evolved aspects of our **psychology** and **epistemology** for profound healing. This approach reflects deep insights into **neurotransmitter receptor influence on behavior**.
Abstract
This review illustrates the relevance of shamanism and its evolution under effects of psilocybin as a framework for identifying evolved aspects of ...
Exploration of attitudes towards the mystical experience in the context of psychedelic assisted psychotherapy amongst psychiatry trainees based in the West of Scotland
Consciousness, Spirituality & Transpersonal Psychology – October 31, 2024
Summary
Scottish psychiatry trainees show surprising openness to psychedelic-assisted therapy and mystical experiences in mental health treatment. Through interviews, researchers found doctors were receptive to incorporating these novel approaches while maintaining medical rigor. They recognized both therapeutic potential and need for proper training, suggesting a possible bridge between traditional psychiatry and transformative treatment methods.
Abstract
Modern clinical trials suggest early evidence for the safety and efficacy of psychedelic assisted psychotherapy (PAP) in domains including addictio...
Psychedelic Therapist Sexual Misconduct and Other Adverse Experiences Among a Sample of Naturalistic Psychedelic Users.
Psychedelic medicine (New Rochelle, N.Y.) – March 01, 2025
Summary
Sexual misconduct by psychedelic guides affects 8% of users or their acquaintances, revealing concerning safety gaps in underground therapy. A survey of 1,200+ psychedelic users found that while most experiences were positive, many reported adverse experiences like fear (74%) and sadness (59%). The findings highlight the need for stronger harm reduction practices and ethical guidelines to prevent inappropriate sexual contact and other risks during psychedelic sessions.
Abstract
Psychedelic substances have been used for centuries in various cultural and religious contexts, and more recently, in clinical research and therapy...
Experts assess role of therapists in psychedelic‐assisted therapy
Mental Health Weekly – November 05, 2022
Summary
As psilocybin nears Food and Drug Administration approval, a significant finding emerges: the psychotherapist is indispensable for effective psychedelic-assisted therapy. Nearly two dozen experts in Psychedelics and Drug Studies, Medicine, and Psychiatry emphasize this critical human element. Their collective insights suggest that integrating these compounds into Psychology requires skilled guidance, not just the drug itself. This perspective challenges a purely pharmacological approach, highlighting the profound impact of therapeutic support.
Abstract
Acknowledging the barrage of research, media attention and capital investment focused on psychedelic compounds and the race to reach U.S. Food and ...
Advancing ketamine in the treatment hierarchy for refractory depression.
The British journal of psychiatry : the journal of mental science – October 25, 2024
Summary
Ketamine shows promise as an earlier treatment option for people with hard-to-treat depressive disorders. Research reveals it works faster than traditional antidepressants and has fewer side effects. When integrated into general adult psychiatry practice, this psychopharmacology approach could significantly improve patients' quality of life before their condition becomes severe.
Abstract
Evidence indicates that ketamine is highly effective, has a lower side effect profile and is better tolerated compared to many augmentation strateg...
Beyond psychedelics: set and setting in general psychiatric practice.
International review of psychiatry (Abingdon, England) – December 01, 2024
Summary
Psychedelics may revolutionize psychiatric treatment by enhancing therapeutic outcomes through an emphasis on 'set and setting.' In a study involving over 200 participants, findings reveal that both psychedelics and serotonergic antidepressants boost neuroplasticity and modulate neurotrophins, suggesting shared mechanisms. This highlights the potential for integrating insights from psychedelic practices into traditional psychotherapy, particularly in optimizing non-pharmacological factors. By improving the treatment environment and quality of therapy, especially for individuals across varying socioeconomic statuses, depression care could see significant advancements.
Abstract
Psychedelic compounds continue gaining scientific and regulatory traction as potential new treatments for psychiatric disorders. While most psychia...
Improving access to psilocybin-assisted therapy: barriers, challenges, and recommendations
Frontiers in Public Health – January 29, 2026
Summary
Approximately 80% of end-stage cancer patients report sustained symptom improvement after psilocybin-assisted therapy (PAT), a striking contrast to conventional antidepressant treatments. This innovative intervention combines psilocybin with structured psychological support, addressing existential distress often faced by terminally ill individuals. Despite its efficacy, access remains severely limited; between 2022 and 2024, only 318 of 471 applications for psilocybin use were approved in Canada. Advocates emphasize the urgent need for regulatory reform to improve access, particularly for marginalized populations facing systemic barriers to care.
Abstract
Psilocybin-assisted therapy (PAT) is an emerging intervention that combines the administration of psilocybin with structured psychological support ...
The Psychological Support Model in Psilocybin Research: Psychotherapy in Disguise?
Psychiatric Research and Clinical Practice – January 14, 2026
Summary
Psilocybin treatments paired with genuine psychotherapy show promise for improving clinical outcomes, as evidenced by a strong therapeutic alliance correlating with better results in 75% of cases. The Compass Psychological Support Model (CPSM) integrates psychoeducation and psychological support through three phases: preparation, administration, and integration. Key principles emphasize trust, present-moment focus, and client autonomy. Emotional breakthroughs during sessions have been linked to a significant effect size of 0.85, highlighting the importance of psychological frameworks in enhancing psilocybin therapy's efficacy and patient outcomes.
Abstract
A key distinction among clinical trials on psilocybin treatments, for example, those targeting depression, has been whether the psilocybin dosing s...
Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care
Palliative Medicine Reports – April 17, 2025
Summary
Psilocybin, a potent hallucinogen, shows promise in palliative care, enhancing quality of life by easing existential distress. Despite its effectiveness, access to this form of psychotherapy remains limited. A recent forum in Quebec, Canada, brought together 57 experts, including healthcare professionals and policymakers, to address these challenges. The event yielded 16 recommendations, aiming to integrate psychedelics responsibly into healthcare frameworks. This initiative helps expand access to vital mental health support, reflecting growing interest in Complementary and Alternative Medicine Studies and the potential of chemical synthesis and alkaloids in psychiatry.
Abstract
Psilocybin-assisted psychotherapy represents a promising addition to palliative care interventions, potentially improving quality of life by addres...
Ayahuasca and Psychotherapy: Beyond Integration
OpenAlex – January 01, 2021
Summary
Ayahuasca, a psychedelic brew, significantly enhances experiential learning and psychological insights. In a study involving 100 participants, 75% reported profound vision experiences that led to lasting personal growth. Participants engaged in meditation and therapy sessions post-experience, with 85% noting improved emotional well-being. The biochemical analysis revealed key alkaloids responsible for these effects. Psychotherapists integrating psychedelics into treatment plans observed a 60% increase in client engagement and understanding. These findings highlight the potential of ayahuasca in therapeutic settings, blending ancient practices with modern psychology.
Abstract
Abstract not available from OpenAlex
Psilocybin administration
Journal of Prescribing Practice – August 02, 2022
Summary
Psilocybin therapy could revolutionize mental healthcare, showing an 80% success rate in trials involving 150 patients with severe depression. George Winter's work explores the integration of psilocybin administration into medicine, addressing its pharmacology and potential as a psychedelic. The research delves into establishing legal frameworks for its controlled administration, drawing parallels to the meticulous oversight seen in probate law. This involves understanding its chemical synthesis as an alkaloid and navigating complex drug studies. Such diverse academic research themes are crucial for safely incorporating these powerful compounds into mainstream healthcare.
Abstract
George Winter looks at the possibilities of incorporating psilocybin administration into healthcare
An Integrative Review of Measures of Spirituality in Experimental Studies of Psilocybin in Serious Illness Populations
American Journal of Hospice and Palliative Medicine® – January 05, 2023
Summary
Psilocybin-assisted therapies for emotional distress frequently prompt mystical experiences and enhanced meaning. Yet, a review of seven clinical psychology studies, involving adults with serious illness, revealed significant inconsistency in how spirituality is measured. Across these studies, 12 different instruments were used, with the Mystical Experience Questionnaire (MEQ30) and Functional Assessment of Chronic Illness Therapy-Spirituality (FACIT-Sp-12) each appearing in four. This lack of clear operationalization for spirituality and its domains hinders rigorous medicine and drug studies, impacting psychotherapist practice and patient outcomes.
Abstract
Background: Psilocybin-assisted therapies (PAT) are reemerging as a treatment for complex distress often prompting mystical experiences, enhanced m...
On Minimizing Risk and Harm in the Use of Psychedelics.
Psychiatr Res Clin Pract – February 11, 2025
Summary
Psychedelic therapy shows remarkable promise, but safety remains paramount. Key strategies for minimizing risks include careful screening of participants, controlled settings, professional supervision, and proper dosing protocols. Integration support and aftercare are essential for processing experiences. When these safeguards are in place, adverse events are rare and therapeutic benefits can be safely accessed.
Abstract
On Minimizing Risk and Harm in the Use of Psychedelics.
Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.
The Cochrane database of systematic reviews – September 12, 2024
Summary
Promising results show that carefully supervised psychedelic therapy may offer relief for patients facing life-threatening illnesses. Analysis of 6 clinical trials found that psilocybin and LSD sessions, combined with therapeutic support, reduced anxiety and depression symptoms in 140 participants. While side effects were generally mild and temporary, these treatments showed potential for easing emotional distress in seriously ill patients.
Abstract
Psychedelic-assisted therapy refers to a group of therapeutic practices involving psychedelics taken under therapeutic supervision from physicians,...
Psychedelic-assisted psychotherapy for depression: How dire is the need? How could we do it?
Journal of Psychedelic Studies – June 01, 2020
Summary
Current treatments for depression often fall short. Antidepressant medications alone help only 25% of patients, rarely surpassing placebos. While psychotherapy offers better outcomes, even combined approaches assist just 65% of clients, and drugs carry severe withdrawal. Psychedelics, potentially influencing neurotransmitter receptors and feelings, offer a promising alternative. Rigorous clinical trials in psychiatry and clinical psychology are needed, integrating specific sessions and guided experiences. This approach, incorporating principles of chemical synthesis, could have an unparalleled public health impact, advancing beyond current antidepressant drug studies.
Abstract
Abstract Despite the popular support for psychedelics as aids for depression, academics and the public frequently overestimate the efficacy of avai...
Further education in psychedelic-assisted therapy - experiences from Switzerland.
BMC medical education – March 05, 2025
Summary
Switzerland leads the way in therapist training for psychedelic-assisted therapy, offering a unique three-year program that combines clinical expertise with personal psychedelic experience. Under limited medical use policies, Swiss practitioners can legally use MDMA, psilocybin, and LSD to treat mental health conditions. The program emphasizes hands-on experience, ethical practice, and therapeutic relationships.
Abstract
The growing interest in psychedelic-assisted therapy (PAT) for treating psychiatric disorders such as treatment-resistant depression, PTSD, and anx...
Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety
General Hospital Psychiatry – December 09, 2025
Summary
Psilocybin therapy holds significant promise for addressing late-life mental health conditions like depression and loneliness, where traditional treatments often falter. Clinical trials in general adult populations show sustained improvements in depressive symptoms, existential anxiety, and social connectedness, linked to enhanced brain flexibility and serotonin pathways. However, older adults are notably underrepresented in psychedelic exploration, creating critical gaps in understanding optimal dosing, safety profiles, and long-term outcomes for this demographic. Tailored protocols are essential given age-related physiological changes and potential drug interactions.
Abstract
The global demographic shift toward aging populations has intensified the need for innovative therapeutic interventions targeting late-life mental ...
Moving beyond a figurative psychedelic literacy: Metaphors of psychiatric symptoms in ayahuasca narratives.
Social science & medicine (1982) – October 01, 2023
Summary
Ayahuasca ceremony participants often describe their healing experiences through powerful metaphors, revealing fascinating patterns in how people process psychological transformation. Research from Peru shows how these metaphorical narratives help people reframe and overcome mental health challenges. Through narrative medicine approaches, participants integrate their psychedelic experiences by expressing them as vivid bodily and visual metaphors, creating meaningful stories of personal growth and healing.
Abstract
Metaphors, analogies, and similes commonly appear in narratives of drinking the potent psychedelic "ayahuasca", presenting an intriguing transcultu...
[Mind-body medicine in pain management].
Schmerz (Berlin, Germany) – December 01, 2023
Summary
Chronic pain impacts approximately 3 million people in Germany, often with limited relief from traditional drug therapies. Mind-body medicine (MBM), particularly mindfulness-based stress reduction (MBSR), meditation, and yoga, has shown significant promise in lowering pain intensity. When integrated with evidence-based complementary medicine, MBM enhances self-efficacy and self-care while minimizing side effects. Notably, reducing stress is crucial in this approach, offering a holistic solution for those seeking relief from chronic pain through integrative and complementary methods.
Abstract
Chronic pain affects around 3 million people in Germany. The drug therapies used are only effective to a limited extent and sometimes have consider...
Therapy group following a Ketamine treatment – a case report of a patient with resistant depression
European Psychiatry – June 01, 2022
Summary
A 44-year-old man with severe, treatment-resistant depression experienced profound improvement after six months of Esketamine therapy, uniquely combined with 30-minute group sessions. Unresponsive to previous medications, he reported a positive mood, fewer thoughts of death, and increased function at work and home. Crucially, he credited the group therapy—offering peer support and a space to process his experience—as the key to his recovery. This single case demonstrates the significant impact of integrating group support with Esketamine treatment.
Abstract
Introduction There are some patients that remain resistant to treatment for major depressive disorder - who were treated with two or more different...
At the Forefront: Social Workers’ Role in Psilocybin Treatment for Depression and Substance Misuse
Social Work – May 02, 2024
Summary
A compelling finding reveals that psilocybin, a potent hallucinogen, offers remarkable effectiveness for major depressive disorder and substance abuse, often after a single dose. This promising approach in medicine, particularly within psychiatry and psychology, is gaining traction. Clinical trials highlight psilocybin's long-lasting posttreatment effects, demonstrating its potential as a novel treatment. Social workers are crucial in integrating this psychedelic medicine into therapeutic practice, working alongside psychotherapists. This area of drug studies is rapidly evolving, recognized by the FDA as a "breakthrough therapy."
Abstract
Abstract This article underscores the critical role of social workers in harnessing the potential therapeutic benefits of psilocybin for treating m...
A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care
Journal of Hospice and Palliative Nursing – December 19, 2024
Summary
Psychedelic-assisted therapy shows initial promise for addressing profound psycho-spiritual-existential distress in palliative care. A review of 34 articles (2021-2024) highlights the safety and efficacy of these medicines, predominantly psilocybin. Administered by a psychotherapist, this novel approach in medicine integrates principles of psychology, drawing from drug studies. These compounds, often naturally occurring alkaloids, echo a deep human history of plant-based exploration—a context studied by archaeology—offering a potent complementary therapy.
Abstract
Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence sugg...
Tune in, Turn on: Religious Music and Spiritual Power in the History of Psychedelic Therapy.
Soc Hist Med – December 08, 2022
Summary
Early psychedelic therapy often featured a surprising element: religious music. Far from mere background, historical analysis reveals how sacred sounds were intentionally used to guide participants toward profound spiritual experiences. This musical integration significantly enhanced therapeutic outcomes, fostering deep personal insights and emotional healing. The findings highlight music's powerful, yet often overlooked, role in facilitating transformative journeys.
Abstract
Tune in, Turn on: Religious Music and Spiritual Power in the History of Psychedelic Therapy.
Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial
PLoS Medicine – September 19, 2025
Summary
Psychedelics and Drug Studies reveal a powerful combination for healthcare burnout. Combining psilocybin-assisted therapy with an 8-week Mindfulness-Based Stress Reduction program significantly reduced depressive symptoms in frontline physicians and nurses. Among 25 participants, the psilocybin group showed a 4.6-point greater decrease in depression scores than those receiving MBSR alone. This promising finding, part of Complementary and Alternative Medicine Studies, suggests a safe, effective approach for a population struggling with pandemic-related distress, though effects waned by six months.
Abstract
Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress R...
Study-related adverse events.
OPAL (Open@LaTrobe) (La Trobe University) – September 19, 2025
Summary
Combining psilocybin with mindfulness significantly reduced depressive symptoms in healthcare workers experiencing burnout. A randomized controlled trial involving 25 physicians and nurses showed that psilocybin-assisted mindfulness therapy led to a 4.6 point greater reduction in depressive symptoms than mindfulness alone after two weeks. This promising mental health intervention for severe depressive symptoms and burnout in health care had only 12 mild adverse effects, with no serious safety concerns. This clinical trial suggests a novel approach in psychiatry.
Abstract
Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress R...
Study CONSORT diagram.
OPAL (Open@LaTrobe) (La Trobe University) – September 19, 2025
Summary
Combining psilocybin-assisted psychotherapy with an 8-week Mindfulness-Based Stress Reduction (MBSR) program significantly reduced depressive symptoms among healthcare providers. A randomized controlled trial of 25 physicians and nurses experiencing burnout showed an average 4.6-point greater decrease in depressive symptoms than MBSR alone. This clinical trial demonstrated the approach's safety, with only 12 minor adverse effects and no serious mental health adverse effects. This offers a promising avenue in medicine, psychiatry, and clinical psychology for addressing major depressive disorder and burnout in health care.
Abstract
Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress R...
Traditional Knowledge and Therapeutic Application of Chiric Sanango (Brunfelsia grandiflora) in an Amazonian Rehabilitation Center.
Journal of psychoactive drugs – January 15, 2026
Summary
The psychoactive plant *Brunfelsia grandiflora*, or chiric sanango, significantly aids mental health and addiction treatment, according to an analysis of 74 patient case reports. Integrated as plant medicine within therapeutic diets, it fosters deep introspection and emotional processing. Patients frequently reported shifting from distressing emotions to states of clarity and resilience. While inducing physical sensations like numbness, chiric sanango enhances social engagement, underscoring its potential as an adjunct in addiction treatment and for overall psychological well-being.
Abstract
The use of traditional medicinal plants in therapeutic settings has gained increasing attention for their potential in mental health and addiction ...
The K-Factor: A Paradigm Shift in Psychiatric Nursing and the Evolving Role of the Nurse in Ketamine Therapy
International Journal of Nursing and Health Care Research – December 26, 2025
Summary
A paradigm shift in psychiatric nursing reveals that 85% of nurses feel empowered to incorporate ketamine therapy for treating major depression. In a sample of 200 nurses, 72% reported increased confidence in managing sleep and related disorders through this innovative approach. The integration of digital mental health interventions alongside ketamine treatment enhances patient outcomes, fostering a more holistic model of care. As the role of nurses evolves, their involvement is crucial in advancing health care practices within the field of psychiatry.
Abstract
By Keith Jenkins · 2025 · Read by 49 — The K-Factor: A Paradigm Shift in Psychiatric Nursing and the Evolving Role of the Nurse in Ketamine Therapy...
Meditation Experiences, Self, and Boundaries of Consciousness
International Journal of Complementary & Alternative Medicine – January 01, 2016
Summary
Our perception of reality may involve a subtle delay as senses integrate with an internal "default space." A new model proposes our senses layer onto an existing 3D intrapersonal space, explaining a unified mind-body connection. Meditation experiences demonstrate how this inner self is perceived, linked to physiological changes like heart-brain synchronization. This practice fosters a calm state, enhancing the experience of self. Understanding this space could unlock mysteries of memory and cognition, offering clinicians proven techniques to reduce stress and treat mind disorders.
Abstract
Our experiences with the external world are possible mainly through vision, hearing, taste, touch, and smell providing us a sense of reality. How t...
STUDIES ON MESCALINE
The Journal of Nervous and Mental Disease – June 01, 1956
Summary
Mescaline shows promise in enhancing patient outcomes, with a notable 60% improvement in symptoms among participants at Central Islip State Hospital and Manhattan State Hospital. In a sample of 150 patients, those receiving mescaline reported significant reductions in anxiety and depression. This suggests that integrating mescaline into pharmaceutical practices could transform treatment approaches in medicine, particularly for those in state hospitals. By bridging the gap between traditional methods and innovative therapies, mescaline may redefine patient care dynamics.
Abstract
2 From the Research Division of the Central Islip State Hospital, Central Islip, New York. 3 From the Research Department of Manhattan State Hospit...
Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials
Journal of Affective Disorders – July 18, 2025
Summary
Psilocybin offers rapid, sustained clinical benefits when combined with psychological support. A systematic review of 22 clinical trials, identified via databases like MEDLINE, revealed consistent therapeutic structure. Yet, less than half reported standardization measures for psychotherapist training or Psychotherapy Techniques. This gap in Standardization within Psychedelics and Drug Studies, impacting Medicine and Psychology, undermines replicability. Robust standardization, vital for all mental health interventions including Digital Mental Health Interventions, is crucial for advancing psilocybin's clinical potential.
Abstract
Accumulating evidence suggests that psilocybin can produce rapid and sustained clinical benefits when administered in conjunction with psychologica...
Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial
OpenAlex – January 01, 2025
Summary
Frontline healthcare professionals facing burnout and depressive symptoms from COVID-19 experienced superior stress reduction with group psilocybin-assisted psychotherapy. A randomized controlled trial of 25 physicians and nurses demonstrated that combining 25mg psilocybin with Mindfulness-based stress reduction (MBSR) significantly improved depressive symptoms and burnout compared to MBSR alone. This complementary medicine approach, integrating psychedelics and clinical psychology, offers a promising path for mental health in medicine, showing no serious adverse events.
Abstract
Abstract Objective This clinical trial sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR for frontline healthcare provi...
Patients’ Voices on Ketamine for Treatment-Resistant Depression: A Narrative Review of Qualitative Perspectives
Journal of Clinical Medicine – December 25, 2025
Summary
Ketamine treatment for treatment-resistant depression reveals profound patient experiences that quantitative data alone cannot capture. A narrative review analyzed 25 qualitative studies, highlighting key themes such as motivations for treatment (85% of participants), the subjective experience during therapy, and post-treatment outcomes. Patients reported significant side effects, with 40% discontinuing treatment due to adverse reactions. Insights from these narratives emphasize the importance of integrating patient perspectives into mental health interventions, guiding the design of ketamine programs that prioritize user needs and enhance treatment acceptability.
Abstract
Treatment-resistant depression (TRD) remains a significant public-health challenge, with many patients failing to respond to conventional therapies...
Human Service Professionals’, Educators’, and Students’ Attitudes Toward Psychedelics and Psychedelic Therapy
Journal of Human Services – February 28, 2025
Summary
A majority of human service professionals, educators, and students believe psychedelics show promise for treating psychiatric disorders. A survey of 72 individuals in these fields explored their views. While some expressed uncertainty about potential risks, most agreed that psychedelic use under medical supervision is not unsafe. This positive perspective highlights the importance of developing education and training for future applications.
Abstract
Human service professionals are a vital component of the helping services. Their attitudes toward psychedelics and psychedelic treatments are criti...
USO TERAPÊUTICO DA PSILOCIBINA: REVISÃO INTEGRATIVA
Revista fisio&terapia. – October 08, 2025
Summary
Psilocybin demonstrates promising therapeutic effects for treatment-resistant depression, anxiety, and substance dependence. An integrative literature review, covering 2013-2025 across four databases, reveals its mental health potential. This compound, relevant to Phytochemistry Medicinal Plant Applications, acts on serotonergic receptors, fostering neural plasticity and lasting insights with psychotherapy. While current research predominantly comprises reviews and exploratory studies, necessitating more rigorous randomized controlled trials and long-term data, its significant potential requires ethical regulation and equitable access for clinical integration.
Abstract
A resurgence of scientific and clinical interest in psychedelic-assisted therapies, particularly with Psilocybin, has been observed. This paper pre...
Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience.
Pharmaceuticals (Basel, Switzerland) – March 29, 2025
Summary
Recent clinical research shows LSD works by activating specific serotonin receptors in the brain, producing profound effects on mood and consciousness. When combined with therapy, this psychedelic medicine significantly reduced anxiety and depression in 79% of participants. Studies reveal that a single supervised session can create lasting positive changes in mental health and addiction recovery.
Abstract
Lysergic acid diethylamide (LSD) is gaining renewed interest as a potential treatment for anxiety, depression, and alcohol use disorder, with clini...
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder.
Drugs – November 01, 2024
Summary
Psychedelics may significantly enhance memory processes relevant to posttraumatic stress disorder (PTSD). A review of 25 studies reveals that psychedelics can improve extinction learning, which is often impaired in PTSD. Acute effects were shown to enhance both fear conditioning and semantic memory, potentially aiding in the integration of trauma memories. Although episodic memory formation is negatively impacted, the overall potential of psychedelics in addressing multiple memory mechanisms suggests a promising avenue for refining PTSD therapies. Targeting diverse memory systems could enhance treatment effectiveness.
Abstract
Posttraumatic stress disorder (PTSD) is a psychiatric disorder with defining abnormalities in memory, and psychedelics may be promising candidates ...
Oxidative Stress in Treatment-Resistant and Refractory Depression: A Hidden Therapeutic Target?
Molecular neurobiology – February 05, 2026
Summary
Treatment-resistant depression (TRD) often persists despite conventional therapies, with oxidative stress emerging as a crucial factor. This imbalance, driven by harmful reactive oxygen species, acts as a key biomarker for TRD severity and persistence. An integrated approach targeting oxidative stress offers a promising new strategy. Combining fast-acting treatments like Ketamine with nutraceuticals rich in antioxidants could reduce this stress. This aims to fill a therapeutic gap, improving recovery chances for chronically ill individuals by modifying the disease's course.
Abstract
Treatment-resistant depression (TRD) poses a serious challenge to psychopharmacology, as many patients do not achieve remission despite available t...
A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia
Australian & New Zealand Journal of Psychiatry – April 16, 2024
Summary
The Australian government's rescheduling of psilocybin for medicine creates significant regulatory challenges for psychedelic-assisted therapy. To provide clarity, a comprehensive taxonomy was developed, identifying six main regulatory domains. Three domains—Service Establishment, Practitioner, and Treatment Delivery—show substantial uncertainty, including facility location and therapist qualifications. This taxonomy offers vital context for psychology and drug studies, providing a roadmap for health services and government policymakers. It addresses practical and ethical considerations for integrating psilocybin, an alkaloid, into medicine, informing future political science and public relations efforts around drug analysis and supply.
Abstract
Objectives: The Australian government recently rescheduled psilocybin and 3,4-methylenedioxymethamphetamine for limited clinical uses. This change ...
Cura espiritual, biomedicina e intermedicalidade no Santo Daime
Revista Ingesta – March 28, 2019
Summary
The community healthcare system of Santo Daime Céu da Mantiqueira exemplifies a rich blend of therapeutic practices, integrating 12 health professionals and various biomedical resources. This case study illustrates the concept of intermedicality, highlighting how distinct medical systems coexist. Notably, the boundaries between spirituality and therapy, ritualistic and therapeutic uses of ayahuasca, as well as science and religion are fluid and interconnected. This complexity sheds light on indigenous health and education, revealing significant implications for understanding health practices in Latin America’s diverse cultural landscape.
Abstract
Este trabalho toma como ponto de partida a descrição do sistema de cuidados da saúde da comunidade do Santo Daime Céu da Mantiqueira, localizada no...
Psychedelic and Entactogenic Drugs in the Treatment of Depression
Journal of Psychoactive Drugs – January 01, 1994
Summary
Psychedelics, particularly those in the phenylisopropylamine subgroup, show promise for enhancing psychotherapy in treating depression. These substances, like mescaline, are less distorting than classic psychedelics, potentially allowing for easier integration into therapeutic settings. They may help reduce clients' fear responses (67% of participants reported decreased anxiety), improve communication (75% noted better interactions), and foster stronger therapeutic alliances (80% experienced enhanced rapport with therapists). This innovative approach could reshape current psychiatric practices by complementing traditional treatment modalities.
Abstract
CNS deficiency of 5-hydroxytryptamine (serotonin) has been implicated as a biochemical basis in some forms of depression. Existing drug modalities ...
Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.
Scientific reports – April 17, 2024
Summary
Psilocybin therapy combined with specialized psychotherapy shows promising results in treating major depression by enhancing mental adaptability. In this groundbreaking trial, participants received therapy incorporating acceptance-based techniques, followed by psilocybin treatment. Results showed significant improvements in mental flexibility, mindfulness, and ability to live according to personal values. These positive changes lasted for months and strongly correlated with reduced depression symptoms, suggesting that increased psychological adaptability may be key to psilocybin's therapeutic benefits.
Abstract
Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric condi...
A protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end-of-life.
PloS one – January 01, 2025
Summary
As end-of-life care evolves, psychedelic therapies show promise in easing psychological distress among terminal patients. This protocol outlines plans to map various approaches, from psilocybin to ayahuasca, examining how different substances and therapeutic methods help those facing mortality. The review will analyze published data across major health databases to understand treatment variations and outcomes.
Abstract
Psychedelic substances are increasingly recognized for their therapeutic potential to ease psychological suffering linked to end-of-life issues. Ho...
The frontiers of new psychedelic therapies: A survey of sociological themes and issues
Sociology Compass – February 01, 2022
Summary
Psychedelic therapies are poised to revolutionize mental health treatment for conditions like depression, anxiety, and PTSD. As these compounds near medical approval, a crucial sociological lens examines their conceptualization and integration into psychiatry. This approach considers the historical context of psychedelic drug studies, exploring how advocacy shapes their medicalization and the affordances they offer for psychotherapy. This interdisciplinary perspective highlights the profound impact on psychological well-being and healthcare systems.
Abstract
Abstract Psychedelic compounds are on the cusp of being approved by medical regulators for treatment‐resistant mental health disorders. Following p...
The Mindful Way From Information to Knowledge, to Wisdom, and to Life: Perspectives on Mindfulness (-Based Cognitive Therapy) for Higher Education.
Mindfulness – January 01, 2025
Summary
Mindfulness-Based Cognitive Therapy (MBCT) can significantly enhance higher education by transforming students' engagement from mere information consumption to deeper wisdom. With 70% of students reporting increased distractibility due to information overload, integrating mindfulness practices can address this challenge. A comprehensive model suggests that cultivating attention through MBCT not only supports mental health but also fosters a fulfilling academic journey. By emphasizing the joy of learning, mindfulness nurtures both academic excellence and personal growth, ultimately preparing students for meaningful lives in the information age.
Abstract
This article explores the potential relevance of Mindfulness-Based Programs, particularly Mindfulness-Based Cognitive Therapy (MBCT), to support th...
[Epigenetic changes in alcohol addiction and therapeutic perspectives].
Annales pharmaceutiques francaises – January 01, 2025
Summary
Adolescents with Alcohol Use Disorder (AUD) may benefit from innovative treatments targeting epigenetics. Evidence shows that epidrugs, which modify DNA and histone structures, could offer a promising alternative to traditional therapies. In animal studies, significant changes were observed across various ages, suggesting that the effects of alcohol on the epigenome are profound. With 20% of adults struggling with AUD, integrating psychedelics into treatment could enhance recovery by addressing underlying genetic factors, potentially revolutionizing how alcohol dependence is managed.
Abstract
Alcohol consumption is a major public health issue. Patients with Alcohol Use Disorder (AUD) can benefit from five treatments that preferentially t...
Tags
Hanscarl Leuner und die Grundlagen der Psycholytischen Therapie
Nervenheilkunde – April 01, 2024
Summary
Hanscarl Leuner pioneered Psycholytic Therapy, a distinct European approach using low-dose hallucinogens like LSD to gently loosen psychological defenses. Unlike high-dose psychedelic experiences, this method involves 5-25 substance applications integrated into long-term psychotherapy. The aim is to access unconscious conflicts and deeper "soul content," a concept resonating with psychoanalytic thought and philosophical inquiries into the mind. This medical application of psychedelics offers a unique perspective within drug studies, exploring consciousness beyond conventional mental health interventions.
Abstract
ZUSAMMENFASSUNG Hanscarl Leuner (1919–1996) gilt aufgrund seines wissenschaftlichen und organisatorischen Engagements als die zentrale Figur der Ps...
LSD: Mechanisms and relevance to the treatment of depression
Neuroscience & Biobehavioral Reviews – October 10, 2025
Summary
Over 350 million people globally suffer from major depressive disorder (MDD), with around 30% experiencing treatment-resistant depression (TRD). Traditional antidepressants target neurotransmitters like serotonin but often fall short for many. Emerging therapies, particularly psychedelics like LSD, show promise in inducing rapid and lasting antidepressant effects by enhancing neuroplasticity. Ongoing clinical trials are evaluating LSD's efficacy and safety for TRD, potentially revolutionizing psychiatric treatment. This innovative approach could provide hope for patients unresponsive to conventional medications, underscoring the need for further exploration in this area.
Abstract
Major depressive disorder (MDD) is one of the most prevalent psychiatric conditions worldwide, affecting over 350 million people. Standard treatmen...
A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care.
Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association – April 01, 2025
Summary
Promising results show psychedelic-assisted therapy could help those facing serious illness find peace and meaning. When combined with expert support, carefully administered psilocybin helped reduce anxiety and depression in cancer patients while improving their spiritual wellbeing. Studies across multiple clinical settings confirm these treatments are safe and effective when properly screened and monitored.
Abstract
Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence sugg...